ArticleVaccine2021
Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships.
Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 89 citations in OpenAlex.
- From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.Vaccines · 2026Article
- Emerging zoonotic threats: HKU5-CoV-2 and the CBRNE approach to pandemic prevention.Infectious diseases & immunity · 2026Review
- Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward.Journal of market access & health policy · 2025Article
- 33 Unresolved Questions in Nanoscience and Nanotechnology.ACS nano · 2025Article
- Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Importance of Targeted Communication Strategies During COVID-19 Vaccination Campaigns in Mozambique: Results of a Mixed-Methods Acceptability Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.Molecular therapy. Nucleic acids · 2025Review
- Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects.Experimental hematology & oncology · 2025Review
- Voices of Nanomedicine: Blueprint Guidelines for Collaboration in Addressing Global Unmet Medical Needs.ACS nano · 2025Review
- Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response.Medicine · 2025Review
- Impact of COVID-19 on Primary Healthcare Research: Trends and Suggestions for Better Services Approaches Via Blockchain Based Applications.Blockchain in healthcare today · 2025Article
- Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review.Human vaccines & immunotherapeutics · 2024Review
- The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.Molecular therapy. Nucleic acids · 2024Review
- A brief review on the lessons learned from COVID-19 on drug discovery and research.Medicine and pharmacy reports · 2024Review
- Social media influence on COVID-19 vaccine perceptions among University students: a Malawi case study.BMC public health · 2024Article
- Article
- Globalization: Embracing global citizenship and the right to migrate.Journal of family medicine and primary care · 2024Article
- Article
- Challenges of biomedical research collaboration in India: Perceptions of Indian and international researchers.PloS one · 2024Article
- Reaching Outer Space and Enabling the mRNA Revolution: A Critical Role of Partnerships for Successful Drug and Vaccine Development.Handbook of experimental pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collaboration is central for initiatives and efforts in the race to fight COVID-19, with particular focus on fostering rapid development of safe and effective COVID-19 vaccines. We investigated the types of partnerships that have emerged during the pandemic to develop these products. Using the World Health Organization's list of COVID-19 vaccine developments, we found nearly one third of all vaccine candidates were developed by partnerships, which tended to use next-gen vaccine platforms more than solo efforts. These partnerships vary substantially between materials-transfer partnerships and knowledge-sharing partnerships. The difference is important: The type of sharing between partners not only shapes the collaboration, but also bears implications for knowledge and technology development in the field and more broadly. Policies promoting fair and effective collaboration and knowledge-sharing are key for public health to avoid stumbling blocks for vaccine development, deployment, and equitable access, both for COVID-19 and expected future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.